EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 264 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Gentle regular exercise could reduce the risk of liver cancer in... February 15, 2021 Adding Apalutamide to Perioperative ADT Associated with Better Outcomes of Radical... June 3, 2026 2023 ASCO Annual Meeting Research Round Up: Progress in Treating Breast... July 27, 2023 The EPA’s Limitations On This Toxic Pesticide Put Children At Risk... February 5, 2021 Load more HOT NEWS Is there a future without Pap testing? First-Line Serplulimab in Combination with Chemotherapy Improves Survival in Patients with... Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite... The ecDNA story – catching the mastermind behind cancer evolution
